News
Important Only
Clearside Biomedical Inc - All Employees To Transition To Consulting Roles - SEC Filing
Clearside Biomedical Inc CLSD.O:CLEARSIDE BIOMEDICAL INC - ALL EMPLOYEES TO TRANSITION TO CONSULTING ROLES - SEC FILINGCLEARSIDE BIOMEDICAL INC - ESTIMATES $3.4 MILLION IN TERMINATION COSTS - SEC FILINGCLEARSIDE BIOMEDICAL INC: REDUCTION IN FORCE IS EXPECTED TO BE COMPLETED DURING Q3 OF 2025Source t...Reuters
Thu, Jul 17
Velocity Clinical Research Strategic Partnership With Palantir To Automate & Streamline Complex Payments Reconciliation Process In Clinical Trials
Palantir Technologies Inc PLTR.O:VELOCITY CLINICAL RESEARCH: STRATEGIC PARTNERSHIP WITH PALANTIR TO AUTOMATE & STREAMLINE COMPLEX PAYMENTS RECONCILIATION PROCESS IN CLINICAL TRIALSReuters
Thu, Jul 17
Clearside Biomedical Announces Plan To Explore Strategic Alternatives To Advance Its Proprietary Suprachoroidal Space (Scs®) Delivery Platform And Promising Ophthalmology Pipeline
Clearside Biomedical Inc CLSD.O:CLEARSIDE BIOMEDICAL ANNOUNCES PLAN TO EXPLORE STRATEGIC ALTERNATIVES TO ADVANCE ITS PROPRIETARY SUPRACHOROIDAL SPACE (SCS®) DELIVERY PLATFORM AND PROMISING OPHTHALMOLOGY PIPELINECLEARSIDE BIOMEDICAL INC: ALTERNATIVES COULD INCLUDE SALE, LICENSE, MONETIZATION, DIVESTI...Reuters
Thu, Jul 17
Morien Receives Notice From Kameron To Explore Sale Of Donkin Mine Interest
Morien Resources Corp MOX.V:MORIEN RECEIVES NOTICE FROM KAMERON TO EXPLORE SALE OF DONKIN MINE INTERESTMORIEN RECEIVES NOTICE FROM KAMERON TO EXPLORE SALE OF DONKIN MINE INTERESTMORIEN RESOURCES CORP - HOLDS 2-4% ROYALTY ON DONKIN MINE COAL SALESReuters
Thu, Jul 17
Sk Bioscience Submits Ind For Phase 1/2 Clinical Trial Of Adjuvanted Influenza Vaccine Candidate
SK Bioscience Co Ltd 302440.KS:SK BIOSCIENCE SUBMITS IND FOR PHASE 1/2 CLINICAL TRIAL OF ADJUVANTED INFLUENZA VACCINE CANDIDATESK BIOSCIENCE CO LTD - INTERIM RESULTS FROM PHASE 1/2 TRIAL EXPECTED BY 2027Reuters
Thu, Jul 17
Harrow Enters Into Commercialization Agreement With Samsung Bioepis For Ophthalmology Biosimilars Portfolio In The United States
Harrow Inc HROW.O:HARROW ENTERS INTO COMMERCIALIZATION AGREEMENT WITH SAMSUNG BIOEPIS FOR OPHTHALMOLOGY BIOSIMILARS PORTFOLIO IN THE UNITED STATESHARROW INC - TO ASSUME COMMERCIAL RESPONSIBILITY FOR BYOOVIZ AND OPUVIZ BY 2025HARROW INC - GAINS EXCLUSIVE U.S. RIGHTS TO OPHTHALMIC BIOSIMILARSReuters
Thu, Jul 17
Roblox Continues To Advance Safety Innovations, Launching Age Estimation, Empowering Teens To Connect With People They Know And Trust, And Additional Features
Roblox Corp (Pre-Reincorporation) RBLX.N:ROBLOX CONTINUES TO ADVANCE SAFETY INNOVATIONS, LAUNCHING AGE ESTIMATION, EMPOWERING TEENS TO CONNECT WITH PEOPLE THEY KNOW AND TRUST, AND ADDITIONAL FEATURESROBLOX: TEENS AGED BETWEEN 13 AND 17 CAN ONLY ADD ADULT USERS (18+) THEY KNOW IN REAL LIFE AS TRUSTED...Reuters
Thu, Jul 17
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Rp-A601 Gene Therapy For Pkp2-Arrhythmogenic Cardiomyopathy
Rocket Pharmaceuticals Inc RCKT.O:ROCKET PHARMACEUTICALS RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FOR RP-A601 GENE THERAPY FOR PKP2-ARRHYTHMOGENIC CARDIOMYOPATHYReuters
Thu, Jul 17
I-Mab Strengthens Givastomig Intellectual Property Portfolio Through Acquisition Of Bridge Health
I-Mab IMAB.O:I-MAB STRENGTHENS GIVASTOMIG INTELLECTUAL PROPERTY PORTFOLIO THROUGH ACQUISITION OF BRIDGE HEALTHI-MAB - BRIDGE HEALTH SHAREHOLDERS MAY RECEIVE UP TO $3.875 MILLION IN MILESTONESI-MAB - TO PAY $1.8 MILLION UPFRONT AND $1.2 MILLION THROUGH 2027Reuters
Thu, Jul 17
Bristol Myers Squibb And Pfizer Announce Direct-To-Patient Eliquis® (Apixaban) Option
Bristol-Myers Squibb Co BMY.N:BRISTOL MYERS SQUIBB AND PFIZER ANNOUNCE DIRECT-TO-PATIENT ELIQUIS® (APIXABAN) OPTIONBRISTOL-MYERS SQUIBB CO - ELIQUIS 360 SUPPORT PROGRAM NOW OFFERS ELIQUIS TO CASH-PAYING PATIENTS AT MORE THAN 40% DISCOUNT TO CURRENT LIST PRICEBRISTOL-MYERS SQUIBB CO - ELIQUIS OFFERED...Reuters
Thu, Jul 17
Hyperscale Data Announces Preliminary Q2 2025 Revenue Of $25.8 Million, Up 45% Year-Over-Year
Hyperscale Data Inc GPUS.A:HYPERSCALE DATA ANNOUNCES PRELIMINARY Q2 2025 REVENUE OF $25.8 MILLION, UP 45% YEAR-OVER-YEARHYPERSCALE DATA INC - REAFFIRMS 2025 REVENUE GUIDANCE OF $125-$135 MILLIONHYPERSCALE DATA: GRESHAM WORLDWIDE EXPECTED TO EMERGE FROM CHAPTER 11 BANKRUPTCY PROCEEDINGS AS A UNIT OF ...Reuters
Thu, Jul 17
Energy Fuels Now Producing Heavy Rare Earth Element Oxides
Energy Fuels Inc UUUU.A:ENERGY FUELS NOW PRODUCING HEAVY RARE EARTH ELEMENT OXIDESENERGY FUELS INC - PRODUCING DYSPROSIUM OXIDE AT 99.5% PURITYENERGY FUELS INC - EXPECTS 15 KG DYSPROSIUM OXIDE BY SEPTEMBER 2025ENERGY FUELS INC - EXPECTS 1 KG TERBIUM OXIDE BY NOVEMBER 2025Reuters
Thu, Jul 17
